Akebia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 78.21. In total, the insiders bought 12 179 900 and sold 1 022 217 AKBA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
78.21
Buy 12 179 900 Shares
Sell 1 022 217 Shares

Historical Insider Trades

Date Type Action Person Amount
Mar 03, 2025 Common Stock Sell Butler John P. 46 409
Mar 03, 2025 Common Stock Sell Burke Steven Keith 7 144
Feb 03, 2025 Common Stock Sell Butler John P. 46 268
Feb 03, 2025 Common Stock Sell Butler John P. 97 982
Feb 03, 2025 Common Stock Sell Burke Steven Keith 23 270
Feb 03, 2025 Common Stock Sell Burke Steven Keith 27 236
Feb 03, 2025 Common Stock Sell Malabre Richard C 30 202
Feb 03, 2025 Common Stock Sell Grund Nicholas 55 621
Jan 31, 2025 Common Stock Buy Butler John P. 701 000
Jan 31, 2025 Stock Option (Right to buy) Buy Butler John P. 1 051 400
Jan 31, 2025 Performance Stock Units Buy Butler John P. 350 500
Jan 31, 2025 Common Stock Buy Burke Steven Keith 194 900
Jan 31, 2025 Stock Option (Right to buy) Buy Burke Steven Keith 292 300
Jan 31, 2025 Common Stock Buy Malabre Richard C 85 000
Jan 31, 2025 Stock Option (Right to buy) Buy Malabre Richard C 128 000
Jan 31, 2025 Common Stock Buy Grund Nicholas 194 900
Jan 31, 2025 Stock Option (Right to buy) Buy Grund Nicholas 292 300
Jan 31, 2025 Common Stock Buy Ostrowski Erik 194 900
Jan 31, 2025 Stock Option (Right to buy) Buy Ostrowski Erik 292 300
Jan 17, 2025 Common Stock Buy Frieson Ron 20 100
Jan 17, 2025 Stock Option (Right to buy) Sell Frieson Ron 20 100
Jun 28, 2024 Stock Option (Right to buy) Buy Ostrowski Erik 500 000
Jun 28, 2024 Common Stock Buy Ostrowski Erik 350 000
Jun 24, 2024 Buy Ostrowski Erik 0
Jun 06, 2024 Common Stock Buy Wolf Myles 30 000
Click to get the best stock tips daily for free!
ABOUT AKEBIA THERAPEUTICS
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...
GOLDEN STAR
Ticker Change Signal Date
MEDP
$300.81
4.30% May 08
BAX
$30.72
3.78% May 07
HBM
$7.41
12.42% May 05
P
PENG
$17.23
9.75% May 05
E
EXE
$105.88
4.76% May 02

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE